The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment

Tamara Tompsett,1 Kate Masters,1,2 Parastou Donyai1 1Department of Pharmacy, University of Reading, Reading, UK; 2Department of Pharmacy, Berkshire Healthcare NHS Foundation Trust, Reading, UK Background: A number of naturalistic studies have investigated paliperidone palmitate (PP) using proxy me...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tompsett T, Masters K, Donyai P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d225ce3f01b4492b99e776fe3b42de58
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d225ce3f01b4492b99e776fe3b42de58
record_format	dspace
spelling	oai:doaj.org-article:d225ce3f01b4492b99e776fe3b42de582021-12-02T01:10:16ZThe utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment1178-2021https://doaj.org/article/d225ce3f01b4492b99e776fe3b42de582018-03-01T00:00:00Zhttps://www.dovepress.com/the-utility-of-novel-outcome-measures-in-a-naturalistic-evaluation-of--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Tamara Tompsett,1 Kate Masters,1,2 Parastou Donyai1 1Department of Pharmacy, University of Reading, Reading, UK; 2Department of Pharmacy, Berkshire Healthcare NHS Foundation Trust, Reading, UK Background: A number of naturalistic studies have investigated paliperidone palmitate (PP) using proxy measures of effectiveness. An unexplored option is to examine the utility of the mental health clustering tool (MHCT), which is used in UK clinical practice to measure patient well-being and is linked to allocation of resources. This study evaluated the effectiveness of PP using the MHCT, the Health of the Nation Outcome Scales (HoNOS), and, for comparison, more conventional outcome measures.Methods: This was a naturalistic, 1-year evaluation of PP (n=50) in schizophrenia as well as a comparator antipsychotic drugs group. Changes in the MHCT cluster-score cost ranking and four HoNOS-derived factors were analyzed using a mixed-model statistical analysis to explore the utility of these measures.Results: At 1 year, 30 patients (60%) continued PP treatment. The mean “cluster-score cost ranking” (–1.5) and Severe Disturbance factor scores (–1.1) were significantly lower (p-value [adjusted] =0.0003, p-value [adjusted] =0.002, respectively) after 1 year of antipsychotic treatment but no differences were found between PP and the comparator antipsychotic drugs group. Patients prescribed PP were 1.8 times (95% CI 1.1–3.1) more likely to be discharged from hospital than those in the comparator antipsychotic drugs group.Conclusion: PP’s continuation rate after 1 year made the study similar to the existing evaluations, and it was possible to prospectively evaluate antipsychotic effectiveness using the novel measures although these did not discriminate between PP and the comparator group. The investigation illustrates that in principle these novel measures are meaningful in naturalistic study designs. Keywords: paliperidone palmitate, antipsychotics, schizophrenia, patient satisfaction, outcome measuresTompsett TMasters KDonyai PDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 681-691 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Tompsett T Masters K Donyai P The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
description	Tamara Tompsett,1 Kate Masters,1,2 Parastou Donyai1 1Department of Pharmacy, University of Reading, Reading, UK; 2Department of Pharmacy, Berkshire Healthcare NHS Foundation Trust, Reading, UK Background: A number of naturalistic studies have investigated paliperidone palmitate (PP) using proxy measures of effectiveness. An unexplored option is to examine the utility of the mental health clustering tool (MHCT), which is used in UK clinical practice to measure patient well-being and is linked to allocation of resources. This study evaluated the effectiveness of PP using the MHCT, the Health of the Nation Outcome Scales (HoNOS), and, for comparison, more conventional outcome measures.Methods: This was a naturalistic, 1-year evaluation of PP (n=50) in schizophrenia as well as a comparator antipsychotic drugs group. Changes in the MHCT cluster-score cost ranking and four HoNOS-derived factors were analyzed using a mixed-model statistical analysis to explore the utility of these measures.Results: At 1 year, 30 patients (60%) continued PP treatment. The mean “cluster-score cost ranking” (–1.5) and Severe Disturbance factor scores (–1.1) were significantly lower (p-value [adjusted] =0.0003, p-value [adjusted] =0.002, respectively) after 1 year of antipsychotic treatment but no differences were found between PP and the comparator antipsychotic drugs group. Patients prescribed PP were 1.8 times (95% CI 1.1–3.1) more likely to be discharged from hospital than those in the comparator antipsychotic drugs group.Conclusion: PP’s continuation rate after 1 year made the study similar to the existing evaluations, and it was possible to prospectively evaluate antipsychotic effectiveness using the novel measures although these did not discriminate between PP and the comparator group. The investigation illustrates that in principle these novel measures are meaningful in naturalistic study designs. Keywords: paliperidone palmitate, antipsychotics, schizophrenia, patient satisfaction, outcome measures
format	article
author	Tompsett T Masters K Donyai P
author_facet	Tompsett T Masters K Donyai P
author_sort	Tompsett T
title	The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
title_short	The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
title_full	The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
title_fullStr	The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
title_full_unstemmed	The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
title_sort	utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/d225ce3f01b4492b99e776fe3b42de58
work_keys_str_mv	AT tompsettt theutilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment AT mastersk theutilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment AT donyaip theutilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment AT tompsettt utilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment AT mastersk utilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment AT donyaip utilityofnoveloutcomemeasuresinanaturalisticevaluationofschizophreniatreatment
_version_	1718403284522237952

The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment

Ejemplares similares